Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
ENTX: Oral anabolic EB613 could close major osteoporosis treatment gaps and improve patient outcomes
Experts highlight a significant gap in osteoporosis treatment due to the limited injectable anabolic options and referral challenges. Entera Bio’s oral anabolic drug, EB613, could offer a solution by improving access, adherence and patient outcomes, with its Phase II data showing comparable efficacy to existing injectable treatments. This development could make a substantial difference for patients by providing a more convenient treatment method.